Loading organizations...
Loading organizations...
Sapyen provides at-home male fertility diagnostic kits, offering comprehensive semen analysis directly to individuals. The core product assesses key reproductive health parameters like sperm count, motility, and morphology. This method uses advanced laboratory testing on home-collected samples, simplifying initial male fertility evaluations and effectively reducing traditional clinical barriers.
Ashwin Ramachandran and Abdul Syed co-founded Sapyen in 2021. Ramachandran’s uncle’s difficult IVF journey revealed the stigma and inaccessibility surrounding male fertility testing. This personal insight, solidified after their meeting at Antler, drove the founders to create a more accessible and user-friendly solution for male reproductive health.
Sapyen primarily serves men trying to conceive, those monitoring post-vasectomy, or individuals proactively managing their reproductive health. Its vision is to empower men globally by making accurate, affordable, and readily available fertility testing. This fosters an informed, proactive approach to male reproductive wellness across all life stages.
Sapyen has raised $140K across 1 funding round.
Sapyen has raised $140K in total across 1 funding round.
Sapyen is a venture-backed MedTech startup developing the world's most accurate, affordable, and convenient at-home male fertility test. The company builds an advanced semen analysis kit powered by its patent-pending SPX72 technology, which extends sperm viability from 1 hour to 3 days for reliable lab analysis after home collection.[1][3][5] It serves men facing fertility challenges—contributing to 50% of infertility cases—who avoid clinical visits due to embarrassment (61% hesitation rate) or access barriers, solving the problem of inaccessible, costly, and inaccurate testing by offering clinician-approved results rivaling labs at lower cost and with privacy.[1][2][5]
Sapyen targets couples planning fertility treatments, with kits stocked in 180+ pharmacies worldwide and $45.5M in exclusive distribution deals with top IVF clinics secured in the last year.[1] Growth momentum includes launching the UK's first at-home kit in October 2025, winning Australia's Most Innovative Healthcare Company 2024, two pending patents, and backing from global VCs in the UK, Singapore, New Zealand, and Australia.[1][4]
Sapyen emerged from the need to democratize male fertility testing, mirroring the over-the-counter pregnancy test revolution that made female diagnostics accessible.[1] Founded as a lean, high-impact team of audacious problem-solvers (headquartered in Dover, Delaware, with operations in Australia and global reach), the company drew inspiration from the fact that male factors cause 50% of fertility issues yet lack simple solutions.[1][2] Key early traction includes rapid commercialization: within 12 months, securing $45.5M in IVF clinic deals, pharmacy stocking as the first clinical-grade home test globally, and the 2024 innovation award.[1]
Pivotal moments include developing SPX72 for extended sperm viability and biotech-AI integration for precise, data-driven insights, leading to the UK launch in 2025 as an NHS alternative amid long clinic wait times.[1][3][4] Recent hires like Dr. Sati Jandu, with 20+ years in fertility tech, signal European expansion.[2]
Sapyen rides the at-home diagnostics boom, fueled by post-pandemic demand for convenient health tech and the $70B fertility market where diagnostics drive 70% of decisions (WHO data).[1] Timing aligns with rising male fertility awareness—50% of cases overlooked due to stigma—and NHS delays, positioning Sapyen as a data-driven disruptor combining biotech, AI, and MedTech for accessible reproductive health.[4][5] Market forces like IVF growth and pharmacy retail expansion favor it, with pharmacy stocking and clinic partnerships amplifying reach.[1]
It influences the ecosystem by normalizing male fertility testing, reducing barriers for 61% of hesitant men, and setting standards for accurate home kits, potentially accelerating global fertility innovation.[1][2]
Sapyen is poised for explosive growth through European expansion (e.g., Dr. Jandu's hire) and further patent leverage, targeting more pharmacy shelves and clinic integrations amid surging at-home health demand.[1][2] Trends like AI-enhanced diagnostics and personalized fertility plans will shape its path, evolving it from test provider to full reproductive health platform. Its influence could redefine male fertility as approachable, much like pregnancy tests did for women—empowering millions while capturing IVF market share.[1][5]
Sapyen has raised $140K in total across 1 funding round.
Sapyen's investors include Antler.
Sapyen has raised $140K across 1 funding round. Most recently, it raised $140K Seed in November 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2021 | $140K Seed | Antler |